Test Price
2,800 AED✅ Home Collection Available
ITGA2B (CD61) Gene Neonatal Alloimmune Thrombocytopenia Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
-
✔
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
-
✔
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
-
✔
Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation.
-
✔
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
-
✔
Price: 2800 AED inclusive of all taxes.
-
✔
Turnaround Time: 3 to 4 Weeks.
Test Overview & Methodology
The ITGA2B gene test employs next-generation sequencing (NGS) to fully analyze the gene encoding integrin alpha-IIb (CD61), the platelet glycoprotein most commonly targeted in neonatal alloimmune thrombocytopenia (NAIT). This definitive genetic assay identifies causative mutations, enabling targeted management and family risk assessment. The test is performed on peripheral blood, cheek swab, or dried blood spot, offering flexibility for neonatal and pediatric patients.
| Features | Our Test (NGS) | Closest Alternative |
|---|---|---|
| Methodology | Next Generation Sequencing – full gene analysis | Targeted mutation panel / Sanger sequencing |
| Diagnostic Precision | >99.9% sensitivity & specificity | ~90% coverage, may miss rare variants |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
Physician Insight & Safety Protocols
“As a medical geneticist, I recognize the profound anxiety families face when neonatal alloimmune thrombocytopenia is suspected. This NGS test provides molecular confirmation, allowing us to tailor treatment with IVIG and platelet transfusions while counseling families about recurrence risk. However, genetic results must always be integrated with clinical and laboratory findings.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Clinical Caution
Do not discontinue any prescribed medication, including immunoglobulin therapy or corticosteroids, without explicit guidance from your treating physician. Abrupt cessation can precipitate severe bleeding episodes.
Patient Safety: Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Recent allogeneic blood transfusion (≤2 weeks) — may confound genetic material extraction.
- Inability to provide legally valid informed consent (minors require guardian consent per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Acute, life-threatening hemorrhage requiring immediate critical care.
Emergency Red Flags (Seek Immediate Medical Attention)
- New onset petechiae, purpura, or mucosal bleeding in a neonate.
- Bulging fontanelle, lethargy, or seizures — signs of intracranial hemorrhage.
- Jaundice with thrombocytopenia in the first 72 hours of life.
Patient FAQ & Clinical Guidance
1. What exactly does the ITGA2B gene test detect?
Answer: This test identifies mutations in the ITGA2B gene causing neonatal alloimmune thrombocytopenia, a potentially fatal bleeding disorder. Using whole-gene sequencing, it pinpoints the exact pathogenic variant inherited by the infant, distinguishing immune-mediated platelet destruction from other neonatal thrombocytopenias. The result guides maternal management in future pregnancies and directs neonatal therapy with matched platelet transfusions.
2. Who should undergo this genetic test?
Answer: Newborns with unexplained severe thrombocytopenia, parents with a previous NAIT-affected pregnancy, and siblings of affected infants to assess carrier status and family risk. All testing of minors in the UAE requires documented guardian consent and genetic counseling, as mandated by Federal Decree-Law No. 4 of 2016 on Medical Liability and the UAE Personal Data Protection Law.
3. How is the sample collected and how long until I receive results?
Answer: A simple blood draw, cheek swab, or a single dried blood spot on an FTA card is collected by our DHA-licensed mobile phlebotomist. Samples are transported under certified cold-chain, and the complete NGS analysis is completed in three to four weeks, with a preliminary verbal report available at two weeks if clinically urgent.
UAE Regulatory & Data Privacy Adherence
- ✔ Test performed in a facility licensed by the Dubai Health Authority (DHA License Number: 1143) – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
- ✔ Full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — security standards for genetic data storage, access, and consent.
- ✔ Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — encrypted electronic health records and secure data exchange.
- ✔ Clinical safety and patient consent governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- ✔ ISO 9001:2015 Quality Management System certified — Cert: INT/EGQ/2509DA/3139.
Clinical & Logistical Metadata
| Test Name | ITGA2B (CD61) Gene Neonatal Alloimmune Thrombocytopenia Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Blood (Whole Blood, EDTA), Cheek Swab (Buccal Mucosa), or Dried Blood Spot on FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Analysis |
| ICD-10-CM Code | P61.0, D69.3, Z13.79 |
| LOINC Code | 82114-0 |
| DHA Facility License & Laboratory Address | DHA License: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians